Important information for the patient.
KETOSTERIL is a medicinal product used in nutritional therapy for patients with kidney function disorders (renal insufficiency).
KETOSTERIL is indicated for the prevention and treatment of the consequences of abnormal or inadequate protein metabolism in adult patients with chronic kidney disease, in combination with limited protein intake in the diet of 40 g/day or less. It is usually used in patients with a glomerular filtration rate (first stage of urine formation) of less than 25 ml/min.
Do not take the medicine:
Caution should be exercised when taking the medicine in patients with phenylketonuria (see section: KETOSTERIL contains phenylalanine). During treatment with KETOSTERIL, your doctor may order regular monitoring of blood calcium levels. When taking KETOSTERIL with aluminum hydroxide, monitor phosphate levels (see section: KETOSTERIL and other medicines). During treatment, you should consume sufficient calories, which is necessary to maintain good health.
There is no sufficient data on the use of KETOSTERIL in children.
Tell your doctor or pharmacist about all medicines you are taking, or have recently taken, and about any medicines you plan to take. To avoid absorption disorders, keep at least 2 hoursintervalbetween taking KETOSTERIL and any of the following medicines that form poorly soluble compounds with calcium:
The medicine should be taken during meals.
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. The decision to use KETOSTERIL in pregnant and breastfeeding women will be made by your doctor.
KETOSTERIL has no effect on the ability to drive and use machines.
The medicine may be harmful to patients with phenylketonuria (a hereditary disorder of metabolism).
This medicine should always be taken exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist. Oral administration.
Unless otherwise prescribed by your doctor, the recommended dose is 4 to 8 tablets 3 times a day. The medicine should be taken during meals. Swallow the tablets whole with a sufficient amount of liquid.
The duration of treatment will be decided by your doctor.
If you have taken more than the recommended dose of the medicine, contact your doctor. So far, no cases of taking more than the recommended dose have been reported.
If you miss a dose, take it as soon as possible. If it is almost time for your next dose, skip the missed dose. Take the next dose at the usual time. Do not take a double dose to make up for a forgotten tablet.
Do not stop taking this medicine without first consulting your doctor. If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The frequency of side effects is defined as follows: very common: more than 1 in 10 patients, common: between 1 in 10 and 1 in 100 patients, uncommon: between 1 in 100 and 1 in 1000 patients, rare: between 1 in 1000 and 1 in 10,000 patients, very rare: less than 1 in 10,000 patients, not known: cannot be estimated from the available data.
If you experience any side effects, including any not listed in this leaflet, please tell your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children. Do not store above 25°C. Store in the original package. Store blisters tightly closed to protect from moisture. Do not use this medicine after the expiry date stated on the carton and blister after: "EXP". The expiry date refers to the last day of the month stated. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The medicine is in the form of yellow, prolonged-release tablets. The tablets are packaged in aluminum/PVC/PVDC blisters in an outer aluminum foil bag, placed in a cardboard box. The pack contains 100 prolonged-release tablets (5 blisters of 20 tablets each) or 300 prolonged-release tablets (15 blisters of 20 tablets each).
Fresenius Kabi Deutschland GmbH, 61346 Bad Homburg v.d.H., Germany
Labesfal, Laboratórios Almiro S.A., Zona Industrial do Lagedo, 3465-157 Santiago de Besteiros, Portugal. For more detailed information, please contact the representative of the marketing authorization holder: Fresenius Kabi Polska Sp. z o.o., Al. Jerozolimskie 134, 02-305 Warsaw, tel.: +48 22 345 67 89. Date of last revision of the package leaflet:23.12.2021
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.